Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Gains from Sales and Divestitures (2016 - 2023)

PharmaCyte Biotech (PMCB) has disclosed Gains from Sales and Divestitures for 9 consecutive years, with $3935.0 as the latest value for Q2 2023.

  • On a quarterly basis, Gains from Sales and Divestitures fell 41.6% to $3935.0 in Q2 2023 year-over-year; TTM through Apr 2023 was $3935.0, a 41.6% decrease, with the full-year FY2023 number at $3935.0, down 41.6% from a year prior.
  • Gains from Sales and Divestitures was $3935.0 for Q2 2023 at PharmaCyte Biotech, roughly flat from $3935.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $11.4 million in Q4 2019 to a low of $2102.0 in Q3 2022.
  • A 5-year average of $2.2 million and a median of $5221.0 in 2022 define the central range for Gains from Sales and Divestitures.
  • Biggest YoY gain for Gains from Sales and Divestitures was 484.62% in 2019; the steepest drop was 53.57% in 2019.
  • PharmaCyte Biotech's Gains from Sales and Divestitures stood at $11.4 million in 2019, then decreased by 0.88% to $11.3 million in 2020, then crashed by 99.97% to $3703.0 in 2021, then decreased by 0.92% to $3669.0 in 2022, then rose by 7.25% to $3935.0 in 2023.
  • Per Business Quant, the three most recent readings for PMCB's Gains from Sales and Divestitures are $3935.0 (Q2 2023), $3935.0 (Q1 2023), and $3669.0 (Q4 2022).